Developmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents
|
|
- Willis Norton
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p Vol. 55, No /11/$12.00 doi: /aac Copyright 2011, American Society for Microbiology. All Rights Reserved. Developmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents Naïm Bouazza, 1,2 *Déborah Hirt, 1,2 Stéphane Blanche, 1,5 Pierre Frange, 1,5 Elisabeth Rey, 3 Jean-Marc Tréluyer, 1,2,3,4 and Saik Urien 1,2,4 EA 3620, Université Paris Descartes, Paris, France 1 ; Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France 2 ; Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin-Saint-Vincent-de-Paul, 3 CIC-0901 Inserm, Cochin-Necker, 4 Paris, France; and Unité d Immunologie Hématologie Pédiatrique, Hôpital Necker Enfants Malades, AP-HP, Paris, France 5 Received 22 November 2010/Returned for modification 16 April 2011/Accepted 28 April 2011 Lamivudine concentration-time courses were described for a very large range of ages to study the effects of body weight and maturation on lamivudine pharmacokinetics and to check the consistency of dosing recommendations. Lamivudine concentrations were monitored on a routine basis to produce concentrations similar to the known values in adults. Concentrations were measured in 580 children from 2 days to 18 years old. A total of 2,106 plasma lamivudine concentrations were measured, and a population pharmacokinetic analysis was performed using the stochastic approximation expectation maximization algorithm implemented in MONOLIX 3.1 software. A two-compartment model adequately described the data. After standardization for a mean standard body weight by using an allometric model, age also had a significant effect on clearance maturation. Typical population estimates (percent interindividual variability) standardized for kg of the apparent clearance, including central and peripheral volumes of distribution, intercompartmental clearance, and absorption rate constant, were 31 liters h 1 (32%), 76.4 liters (77%), 129 liters, 5.83 liters h 1, and h 1, respectively. According to the model, elimination clearance (liters/h/ kg) increases gradually during the first years of life. Theoretical doses needed to reach the range of 24 h of exposure observed in adults were calculated: to be closer to adult exposure, children should receive 4 mg/kg/day from birth to 8 weeks of age, 5 mg/kg/day from 8 to 16 weeks of age, 6 mg/kg from 16 to 25 weeks of age, 8 mg/kg/day from 25 weeks of age to 14 kg of body weight, 150 mg/day from 14 to 25 kg of body weight, 225 mg/day from 25 to 35 kg of body weight, and 300 mg/day thereafter. Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (NRTI). Following an oral dose, lamivudine is rapidly absorbed and has a wide distribution due to its relatively low molecular mass (229 Da) and low plasma protein binding ( 36%). The majority of lamivudine (approximately %) is eliminated unchanged in the urine over 24 h (12). Approximately 5 to 10% is metabolized to the pharmacologically inactive trans-sulfoxide metabolite, the majority of which is also excreted in the urine within 12 h after a single oral dose (12). Lamivudine is used for treatment of human immunodeficiency virus type 1 (HIV-1) infection in a very wide range of ages, from neonates to adults. Although the pharmacokinetics is quite well described in adults, limited studies are available on lamivudine pharmacokinetics in very young children. Dosing recommendations are based on the hypothesis of the immaturity of renal function in newborns; thereby, the usual standard lamivudine dose is 4 mg/kg of body weight/day within 6 weeks after birth and 8 mg/kg/day thereafter (24). For older children, the current recommended doses are 150 mg/day from 14 to 21 kg, 225 mg/day from 21 to 30 kg, and 300 mg/day thereafter (24). In the present study, we have developed a population pharmacokinetic model for lamivudine in a large group of children from neonates to adolescents in order to * Corresponding author. Mailing address: Unité de Recherche Clinique, Hôpital Tarnier, 89 Rue d Assas, Paris, France. Phone: Fax: naim.bouazza@cch.aphp.fr. Published ahead of print on 16 May determine the relationship between lamivudine pharmacokinetics and age or body weight and to investigate the consistency of the current recommended pediatric dosage regimen. MATERIALS AND METHODS Patients and treatment. The population comprised 580 pediatric patients, ranging in age from 2 days to 18 years (median, 7.41 years) and in body weight from 1 to 84 kg (median, 23 kg). Children received lamivudine as tablet or oral solution for the treatment of HIV infection or for the prevention of mother-tochild transmission. The median (standard deviation [SD]) lamivudine dose was 7.5 (3.2) mg kg 1 /day. Ethics committee approval and patient consent are not compulsory in France in order to retrospectively use therapeutic drug monitoring data, so no informed consent had to be collected. Analytical method. Lamivudine was measured in a 100 l plasma sample by high-performance liquid chromatography. An internal standard was used. Lamivudine was extracted by solid-phase extraction on a Bond Elut C 18 column, and separated on a Satisfaction C 8 Plus column (250 by 3 mm) with a gradient of solvent A (water with 0.01% trifluoroacetic acid, 2% methanol, and 3% acetonitrile) and solvent B (acetonitrile) as follows: 50% solvent A and 50% solvent B for 30 min, 90% solvent A and 10% solvent B for 30 min, and 98% solvent A and 2% solvent B for 30 min. UV absorbance at 2 nm was used for detection the detection of lamivudine. The limit of quantification (LOQ) was 0.02 mg/liter. The mean interassay precision at the low-quantity controls was 10%, and inaccuracy at the LOQ was 4.5%. Overall recovery was 65%. Modeling strategy and population pharmacokinetic model. Data were analyzed using the nonlinear mixed effect modeling software program Monolix, version 31s ( (14). Parameters were estimated by computing the maximum likelihood estimator of the parameters without any approximation of the model (no linearization) using the stochastic approximation expectation maximization (SAEM) algorithm combined with a Markov chain Monte Carlo (MCMC) procedure. The number of MCMC chains was fixed to 10 for all estimations. The between-subject variabilities (BSV [ ]) were ascribed to an exponential model. Parameter shrinkage was calculated as {1 SD( )/ }, where SD( ) and are the standard deviation of individual pa- 3498
2 VOL. 55, 2011 LAMIVUDINE POPULATION PHARMACOKINETICS IN CHILDREN 3499 FIG. 1. Observed lamivudine concentrations (E) and population predicted lamivudine concentrations (curve) in log scale as a function of time for BID and OAD regimens. Asterisks represent concentrations below the limit of quantification. rameters and the population model estimate of the BSV, respectively (22). The likelihood ratio test (LRT) including the log likelihood, the Akaike information criterion (AIC), and the Bayesian information criterion (BIC) were used to test different hypotheses regarding the final model, covariate effects on pharmacokinetic parameters, the residual variability model (proportional versus proportional plus additive error model), and the structure of the variance-covariance matrix for the BSV parameters. The main covariates of interest in the population were postnatal age (PNA), body weight, postmenstrual age (PMA; PMA PNA gestational age), and the formulation. Gestational age has been set to 40 weeks when the information was not available. Age-related change functions for clearance (CL) or volume of distribution (V) as a function of PNA or postmenstrual age have been described in detail (2, 9, 21). Parameter estimates were standardized for a mean standard body weight by using the allometric model P i P STD (BW i /BW STD ) PWR, where P STD is the standard value of parameter for a patient with the standard body weight (BW STD ) value and P i and BW i are the parameter and body weight, respectively, of the ith individual. The PWR (power) exponents may be estimated from the data. However, from allometric scaling theory these are typically 0.75 for clearance parameters and 1 for volumes of distribution (2). Galenic form was tested as a categorical covariable (CA) on bioavailability in order to point out a difference between oral tablet and solution according to CL CL CA. For evaluation of the goodness of fit, the following graphs were performed for the final model: observed and predicted concentrations versus time, observed concentrations versus population predictions, weighted residuals versus time, and weighted residuals versus predictions. Similar graphs using individual predictive estimation were examined. Diagnostic graphics were obtained using the R program (11). A repeated-measures analysis of variance (ANOVA), performed using the nlme package (20) with the R program, was used to test possible differences between a once-a-day (OAD) regimen and a twice-a-day (BID) regimen. Visual predictive check (VPC) validation. Lamivudine concentration profiles were simulated and compared with the observed data to evaluate the predictive performance of the model. Simulated concentrations were then compared with the observed data to evaluate the predictive performance of the model. The vector of pharmacokinetic parameters was simulated by using the final model. Each vector parameter was drawn in a log-normal distribution with a variance corresponding to the BSV previously estimated. A simulated residual error was added to each simulated concentration. All observed and simulated concentrations were standardized for a lamivudine dose of 80 mg for the BID regimen and 160 mg for the OAD regimen as dose proportionality of lamivudine pharmacokinetics has previously been demonstrated (12). The 5th, 50th and 95th percentiles of the simulated concentrations at each time were then overlaid on the observed concentration data, and a visual inspection was performed. The variability was reasonably estimated if the 95% confidence interval (95% CI) for the proportion of observed data outside the bounds included the theoretical value of 10%. Dose simulations. The theoretical dose needed to reach the range of 24 h of exposure in adults observed from previous studies (from 8.9 to 16.6 mg h/liter) (7, 24) of the function of age in weeks and body weight (for the older patients) was calculated from our model. Recommended doses were then derived and simulated in each group, the area under the concentration-time curve from 0 to 24 h (AUC 0 24 ) values obtained from the simulations were compared to the range of the previously described values for AUC 0 24 in adults obtained following an administration of 300 mg of lamivudine OAD (7, 24). RESULTS Demographic data. A total of 580 patients and 2,106 plasma drug concentrations were available for pharmacokinetic evaluation. The mean time of follow-up was 2.5 months. Population pharmacokinetics. A total of seven concentrations were below the limit of quantification (BLQ). A twocompartment model adequately described the data (Fig. 1), and thus the apparent parameters of the model were the clearance (CL/F), the central volume of distribution (V c /F), the peripheral volume of distribution (V p /F), the intercompartmental clearance (Q/F), and the absorption rate constant (K a ) (Table 1). F is the unknown bioavailability. The proportional plus additive error model displayed a nonsignificant additive part, and thus residual variability was described by a proportional error model. Intersubject variability was described by the exponential error model and retained only for apparent clearance and central volume of distribution. Samples were obtained at different occasions; the number of samples per occasion was 1 and did not allow estimation of interoccasion variability. The allometric scaling of clearance (CL and Q) and volume (V c and V p ) terms improved the goodness of fit. After the inclusion of the allometric scaling, age also had a significant effect on clearance. Thus, the final covariate model on the parameters was:
3 3500 BOUAZZA ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. Population pharmacokinetic parameters of lamivudine standardized for a body weight of kg by using an allometric model in 580 HIV-1-infected children a Parameter Mean RSE (%) Structural model K a (h 1 ) CL/F (liters/h) 31 2 V c /F (liters) Q/F (liters/h) V p /F (liters) PMA 50 (wk) 59 4 Statistical model CL/F Vc /F (proportional) a RSE, relative standard error (standard error of estimate/estimate 100); K a, absorption rate constant; CL/F, apparent elimination clearance; V c /F, apparent central volume of distribution; V p /F, apparent peripheral volume of distribution; Q/F, intercompartmental clearance;, proportional residual variability estimate;, interindividual variability estimates;, power term for the effect of age on clearance; PMA 50, PMA at which clearance reaches 50% of the adult sizeadjusted value. The typical parameters refer to an adult patient weighing kg according to the allometric model value typical parameter (body weight/ ) PWR, where PWR 0.75 for the CL and Q terms and 1 for the V c and V p terms. This value is multiplied by the PMA effect, PMA /(PMA PMA 50 ), for CL/F. CL/F CL BW 0.75 PMA 50 V C /F Vc BW PMA PMA Q/F Q BW 0.75 V p /F Vp BW according to the model, the values for PMA 50 and were 59 weeks and 3.02, respectively, where PMA 50 is the PMA at which clearance reaches 50% of the adult size-adjusted value and is the power term for the effect of age on clearance. Figure 2 displays the variation of clearance (liters/h/ kg) as a function of age. The apparent elimination clearance increases gradually from birth to the first years of age. The galenic form had no significant effect. Table 2 displays the AUC 0 24 minimum and maximum concentrations (C min and C max, respectively) resulting from the BID and OAD regimens. The OAD C min were significantly lower than those observed with the BID regimen: they decreased by 54.5% and 53.3% for children and adolescents, respectively. The OAD C max were significantly higher than those observed with the BID regimen: they increased by 72.7% and 58.3% for children and adolescents, respectively. The 24-h exposures were not significantly different in children (P 0.75) and adolescents (P 0.20). Table 1 summarizes the final population pharmacokinetic estimates. All of the parameters were well estimated, given their percent relative standard error (RSE). The -shrinkages for CL/F and V c /F were 0.19 and 0.39, respectively, indicating that the empirical Bayesian estimates for individual parameters are reliable for clearance but not for volume of distribution, which had a shrinkage value greater than Downloaded from on May 14, 2018 by guest FIG. 2. Apparent elimination clearance expressed in liters/h/ kg (E) as a function of age. The line represents the equation defined by the model.
4 VOL. 55, 2011 LAMIVUDINE POPULATION PHARMACOKINETICS IN CHILDREN 3501 Parameter TABLE 2. Comparison of pharmacokinetic parameters obtained from BID and OAD regimens Children (1 11 yr old) (n 302) BID (4 mg/kg q12h) OAD (8 mg/kg q24h) Median (SD) result for dose regimen shown: P value (ANOVA) Adolescents ( 12 yr old) (n 114) BID (150 mg q12h) OAD (300 mg q24h) P value (ANOVA) AUC 0 24 (mg h/liter) 12.5 (4.0) 11.1 (3.8) (3.8) 12.8 (3.6) 0.20 C min (mg/liter) 0.11 (0.12) 0.05 (0.11) (0.09) 0.07 (0.06) 10 4 C max (mg/liter) 1.1 (0.23) 1.9 (0.47) (0.32) 1.9 (0.44) % (13). However, doses were simulated in order to achieve a target AUC. The estimation of individual AUC is only based on individual clearance. Table 3 summarizes lamivudine AUC 0 24 and CL/F in the present and previous studies for different age groups. Evaluation and validation. Figure 3 (VPC) shows that the average prediction matches the observed concentration time courses and that the variability is reasonably estimated. The numbers (percentages) of observed points within the 90% prediction interval for every 12 h (q12h) and q24h were 1,639/ 1,804 (90.8%) and 254/289 (87.8%), respectively. Dose simulations. Figure 4 displays the theoretical dose needed to reach the range of 24 h of exposure observed from previous adult studies (from 8.9 to 16.6 mg h/liter) (7, 24) as a function of age in weeks and body weight (for the older patients) according to our model. To be closer to adult exposure, the lamivudine doses in children appear to be 4 mg/kg/day from birth to 8 weeks of age, 5 mg/kg/day from 8 to 16 weeks, 6 mg/kg from 16 to 25 weeks, 8 mg/kg/day from 25 weeks of age to 14 kg of body weight, 150 mg/day from 14 to 25 kg, 225 mg/day from 25 to 35 kg, and 300 mg/day thereafter. Table 4 displays the simulated AUC 0 24 obtained with our dosing recommendations in each group. According to follow-up time, a patient can be included in successive groups. From neonates to adolescents, the AUC 0 24 values obtained were in the range of previously described values in adults. As shown in Fig. 5, AUC 0 24 values obtained from 400 Monte Carlo simulations with our dosing recommendation were all included in the AUC 0 24 adult range. However, the AUC 0 24 values derived from the FDA recommendation led to pediatric exposure over the AUC 0 24 adult range, especially in the newborns. DISCUSSION This article describes lamivudine pharmacokinetics in 580 children from 2 days to 18 years of age. Lamivudine concentrations were satisfactorily described by a two-compartment model. Lamivudine freely penetrates tissue beyond the systemic circulation and is able to distribute through a peripheral compartment (12, 19). The apparent elimination clearance and AUC 0 24 in each age group were consistent with those in previous studies (Table 3). The apparent elimination clearance (CL/F 31 liters/h/ kg) was consistent with previous adult studies: 29.6 liters/h (18) and 26.7 liters/h (10). The apparent volume of distribution (central plus peripheral) was consistent with previous adult studies: liters/ kg versus 128 liters (17) and 238 liters (5). The population model was also used to investigate the effect of growth (body weight) and maturation (age) on pharmacokinetic parameters. In our model, after allometric scaling of TABLE 3. Comparison of lamivudine derived pharmacokinetic parameters CL/F and AUC 0 24 between our study and the latest publications on HIV-1-infected children according to age group Age group (n) Median (SD) daily dose (mg/kg) CL (liters/h/kg) Median (95% CI) AUC 0 24 (mg h/liter) Source or reference Newborns 1 mo (77) 4 (7.2) 0.26 ( ) 16.7 ( ) This study 3 28 days (40) ( ) 12.0 ( ) 23 1 day (16) ( ) 19.6 ( ) 16 7 days (16) ( ) 15.8 (14 18) 16 Infants 1 yr (45) 7 (5.2) 0.49 ( ) 13.0 ( ) This study 29 days to 3 yr (59) ( ) 13.6 ( ) 23 Children 1 11 yr (426) 7.7 (2.6) 0.64 ( ) 12.2 ( ) This study 2 13 yr (19) ( ) 8.9 ( ) yr (17) ( ) 7.4 ( ) 8 Adolescents yr (129) 6.7 (2.5) 0.49 ( ) 13.1 ( ) This study 7 18 yr (34) ( ) 13.0 ( ) 8
5 3502 BOUAZZA ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 3. Evaluation of the final model: comparison between the 95% confidence intervals (95% CI) of the 5th, 50th, and 95th percentiles obtained from 1,000 simulations (lines) and the percentiles calculated from the observations for lamivudine concentrations standardized for lamivudine doses of 80 mg and 160 mg, respectively, for the BID (A) and OAD (B) regimens. the parameters, an effect of age, PMA, on clearance was also observed. The PMA parameters for the clearance, and PMA 50, are similar to those reported for vancomycin (3). The PMA 50 found in this study for lamivudine (59 weeks) is greater than the PMA 50 of 48 weeks reported for maturation of the glomerular filtration rate (GFR) (21). The clearance of 31 liters/h/ kg for a drug that is % eliminated by the kidney and not highly protein bound means that it must be excreted by tubular secretion. The later maturation of lamivudine clearance may suggest that tubular secretion develops later than the GFR. On the other hand, the discrepancy between the rate of maturation of GFR and maturation of lamivudine CL/F should be addressed also as follows: older infants may have a lower CL/F than the value that could be expected from PMA and FIG. 4. The gray areas represent the doses of lamivudine (mg/kg/24 h) needed to reach the range for the AUC 0 24 values observed in adults (from 8.9 to 16.6 mg h/liter) as a function of age (A) and body weight (B). The bold lines represent our dosing recommendations.
6 VOL. 55, 2011 LAMIVUDINE POPULATION PHARMACOKINETICS IN CHILDREN 3503 TABLE 4. Simulated exposures obtained from our recommended lamivudine doses according to age and/or body weight Group by age and/or body wt (n) Total daily dose Median (SD) AUC 0 24 (mg h/liter) a 8 wk (82) 4 mg/kg 13.4 (6.2) 8 16 wk (13) 5 mg/kg 12.1 (4.8) wk (17) 6 mg/kg 12.2 (6) 25 wk to 14 kg (113) 8 mg/kg 12.2 (5.6) kg (241) 150 mg 12.3 (5.1) kg (192) 225 mg 14.1 (5.9) 35 kg (149) 300 mg 13.8 (5.5) a For comparison, the adult range of AUC 0 24 values was 8.9 to 16.6 mg h/ liter (7, 24). weight alone because they would be sicker, having been infected longer with HIV. According to this model, clearance increases gradually up through the first years of age. This relationship between lamivudine clearance and age was supported by the study by Tremoulet et al. (23), which demonstrated the rapid maturation of renal function occurring from birth and persisting during the subsequent few weeks of life. The variation in lamivudine clearance could be explained by the progressive maturation of renal function with age and body weight during the first years of life. No relationship between concentration and efficacy of lamivudine in children has been successfully demonstrated. Thus, we considered the range of AUC 0 24 values observed in adults from previous studies following administration of 300 mg OAD of lamivudine (7, 24). Considering this range of AUC 0 24 values, the calculated dose needed to reach this adult exposure according to age shows that the transition from 4 mg/kg/day to 8 mg/kg/day at 6 weeks of age (FDA recommendation) should be reconsidered. Our simulations show that a dosing scheme gradually increasing the dose (mg/kg) according to weeks of age seems to maintain exposure closer to that in the adult and better reflects the maturation of renal function occurring from birth and persisting during the first weeks of life. The actual FDA recommendations for lamivudine in older children (150 mg/day from 14 to 21 kg of body weight, 225 mg/day from 21 to 30 kg, and 300 mg/day thereafter) are close to our recommendations. In conclusion, this study reports lamivudine pharmacokinetics in children ranging from neonates to adolescents. The pharmacokinetic parameters were Downloaded from on May 14, 2018 by guest FIG. 5. Median AUC 0 24 obtained from 400 Monte Carlo simulations with our dose recommendation and from the FDA recommendation as a function of age and body weight. The gray areas represent the ranges for AUC 0 24 observed in adults (from 8.9 to 16.6 mg h/liter). Asterisks correspond to AUC 0 24 values outside the adult range.
7 3504 BOUAZZA ET AL. ANTIMICROB. AGENTS CHEMOTHER. consistent with those from previous studies. The lamivudine elimination clearance is related to the maturation of renal function and varies as a function of age and body weight. Moreover, this modeling reflects fully mature adult values. According to simulations, to be closer to adult exposure, children should receive the following lamivudine doses: 4 mg/kg/ day from birth to 8 weeks of age, 5 mg/kg/day from 8 to 16 weeks of age, 6 mg/kg from 16 to 25 weeks of age, 8 mg/kg/day from 25 weeks of age to 14 kg of body weight, 150 mg/day from 14 to 25 kg of body weight, 225 mg/day from 25 to 35 kg of body weight, and 300 mg/day thereafter. ACKNOWLEDGMENT We acknowledge the Pediatric European Network Treatment AIDS Laboratory Network (PENTA-LABNET) for financial support. REFERENCES 1. Reference deleted. 2. Anderson, B. J., and N. H. G. Holford Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48: Anderson, B. J., K. Allegaert, J. N. Van den Anker, V. Cossey, and N. H. Holford Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63: Reference deleted. 5. Benaboud, S., et al Pregnancy-related effects on 3TC pharmacokinetics: a population study with 228 women, abstr th Conf. Retrovir. Opportunistic Infect. 6. Bergshoeff, A., et al Plasma pharmacokinetics of once- versus twicedaily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir. Ther. 10: Bruno, R., et al Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin. Pharmacokinet. 40: Burger, D. M., et al Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin. Pharmacol. Ther. 81: Chen, N., K. Aleska, C. Woodland, M. Rieder, and G. Koren Ontogeny of drug elimination by the human kidney. Pediatr. Nephrol. 21: Heald, A. E., et al Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40: Ihaka, R., and R. Gentleman R: a language for data analysis and graphics. J. Comput. Graph. Stat. 5: Johnson, M. A., K. H. Moore, G. J. Yuen, A. Bye, and G. E. Pakes Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36: Karlsson, M. O., and R. M. Savic Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82: Kuhn, E., and M. Lavielle Maximum likelihood estimation in nonlinear mixed effects models. Comput. Stat. Data Anal. 49: Reference deleted. 16. Moodley, D., et al Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J. Clin. Pharmacol. 41: Moore, K. H., et al Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob. Agents Chemother. 43: Moore, K. H., et al Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59: Mueller, B. U., et al Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 42: Pinheiro, J. C., and D. M. Bates Mixed-effects models in S and S-PLUS. Springer Verlag, New York, NY. 21. Rhodin, M. M., et al Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24: Savic, R. M., and M. O. Karlson Shrinkage in empirical Bayes estimates for diagnostics and estimation. Population Approach Group Europe, Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. 23. Tremoulet, A. H., et al Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob. Agents Chemother. 51: ViiV Healthcare UK, Ltd. 25 October 2010, posting date. Epivir, summary of product characteristics. ViiV Healthcare UK, Ltd., Uxbridge, Middlesex, United Kingdom. Downloaded from on May 14, 2018 by guest
Pregnancy-Related effects on Tenofovir Pharmacokinetics: A Population Study with 186 women.
AAC Accepts, published online ahead of print on 28 November 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.05244-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPopulation Pharmacokinetics of Abacavir in Pregnant Women
AAC Accepts, published online ahead of print on 28 July 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03469-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Population
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.8.3118.x An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and
More informationQuinine Pharmacokinetics and Pharmacodynamics in Children with Malaria Caused by Plasmodium falciparum
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3658 3662 Vol. 49, No. 9 0066-4804/05/$08.00 0 doi:10.1128/aac.49.9.3658 3662.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationDevelopment and Evaluation of Bayesian Software for Improving Therapeutic Drug Monitoring of Gentamicin in Neonates
Development and Evaluation of Bayesian Software for Improving Therapeutic Drug Monitoring of Gentamicin in Neonates Eva Germovšek, Alison Kent, Nigel Klein, Mark A Turner, Mike Sharland, Elisabet Nielsen,
More informationAntiviral Therapy 2012; 17:25 33 (doi: /IMP1915)
Antiviral Therapy 202; 7:25 33 (doi: 0.385/IMP95) Original article Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationEnvironmental Variability
1 Environmental Variability Body Size, Body Composition, Maturation and Organ Function Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand the major sources
More informationReferences: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE0120 2. Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected
More informationScaling Renal Function in Neonates and Infants to Describe the Pharmacodynamics of Antibiotic Nephrotoxicity
Scaling Renal Function in Neonates and Infants to Describe the Pharmacodynamics of Antibiotic Nephrotoxicity Nick Holford University of Auckland Catherine Sherwin University of Utah Outline What does Scaling
More informationJoint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3423 3431 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01487-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Joint
More informationA population pharmacokinetic model for rifampicin auto induction
A population pharmacokinetic model for rifampicin auto induction Paolo Denti 1, Wynand Smythe 1, Ulrika SH Simonsson 2, Roxana Rustomjee 3, Philip Onyebujoh 4, Peter Smith 1, Helen McIlleron 1 1 Division
More informationChildren are small adults and babies are young children
1 Children are small adults and babies are young children Nick Holford Dept Pharmacology & Clinical Pharmacology Brian Anderson Dept Anaesthesia & Starship Hospital University of Auckland, New Zealand
More informationAge-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2006, p. 910 916 Vol. 50, No. 3 0066-4804/06/$08.00 0 doi:10.1128/aac.50.3.910 916.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationPharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines
Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines Paolo Denti, Carmen Gonzalez-Martinez, Jana Winckler, Adrie Bekker, Heather Zar, Gerry Davies, Annelies van
More informationTranslational PK M&S for the assessment of duration of contraceptive cover after use of miltefosine for the treatment of visceral leishmaniasis
Translational PK M&S for the assessment of duration of contraceptive cover after use of miltefosine for the treatment of visceral leishmaniasis Thomas Dorlo, Manica Balasegaram, Nines Lima, Peter de Vries,
More informationPublic Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir
Public Assessment Report EU worksharing project paediatric data Valcyte Valganciclovir Currently approved indication(s): Pharmaceutical form(s) affected by this project: Strength(s) affected by this variation:
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationDEVELOPMENTAL PK/PD: WHAT HAVE WE LEARNT? Geoff Tucker
DEVELOPMENTAL PK/PD: WHAT HAVE WE LEARNT? Geoff Tucker UNDERSTANDING AND PREDICTING PK/PD IN JUVENILES PHARMACOKINETICS Can we scale from juvenile animals? Can we scale from allometry? Can we scale from
More informationPKPD Changes with Age
1 PKPD Changes with Age Body Size, Body Composition, Maturation and Organ Function, Targets & Receptors Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationPopulation pharmacokinetics of total and unbound plasma cisplatin in adult patients
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2004.02082.x Population pharmacokinetics of total and unbound plasma cisplatin in adult patients Sail Urien 1,2 & François Lokiec 1 1 Laboratoire
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMultiple Interactions of Cimetidine and Probenecid with Valaciclovir and Its Metabolite Acyclovir
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2002, p. 458 463 Vol. 46, No. 2 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.2.458 463.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationPediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationCCC ARV Dosing Recommendations for HIV-exposed infants Updated
USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for
More informationPlasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5294 5299 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.05317-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Plasma
More informationAnakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
Urien et al. BMC Pharmacology and Toxicology 2013, 14:40 RESEARCH ARTICLE Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research J. Chem. Pharm. Res., 2010, 2(5): 45-51 ISSN No: 0975-7384 CODEN(USA): JCPRC5 Simultaneous U.V. Spectrophotometric estimation
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationRegulatory experience in application of modelling in dose selection
Regulatory experience in application of modelling in dose selection Elisabeth Rook, MEB-CBG, The Netherlands EMEA WORKSHOP ON MODELLING IN PAEDIATRIC MEDICINES 14-15 April 2008 Pediatric Applications based
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE
APRIL 2011 PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Methicillin-Resistant Staphylococcus 2
More informationPharmacotherapy Issues in the Pediatric Population
Pharmacotherapy Issues in the Pediatric Population Continuing Professional Pharmacy Development Dr. Shane Pawluk, PharmD Dr. Andrea Cartwright, PharmD Dr. Maryam Khaja March 26, 2014 Outline Didactic Session
More informationBioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method
Asian Journal of Chemistry Vol. 19, No. 6 (2007), 4245-4250 Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method K.V. SUBRAHMANYAM*, P. MOHANRAJ, P. SANDHYARANI, V.S. SARAVANAN
More informationModule Summary of Clinical Pharmacology
Module 2.7.2 Summary of Clinical Pharmacology Copyright 2003 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 2 TABLE OF CONTENTS
More informationOptimizing Drug Exposure
Optimizing Drug Exposure All Patients Are Not Average Michael Neely, MD, MSc Associate Professor, Pediatrics Keck School of Medicine, University of Southern California Laboratory of Applied Pharmacokinetics
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationPOPULATION PHARMACOKINETICS. Population Pharmacokinetics. Definition 11/8/2012. Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development.
/8/202 POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug
More informationEuropean public MRL assessment report (EPMAR)
15 November 2016 EMA/CVMP/351687/2016 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) (bovine species) On 17 October 2016 the European Commission adopted
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationMODULE PHARMACOKINETICS WRITTEN SUMMARY
MODULE 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY m2.6.4. Pharmacokinetics Written Summary 2013N179518_00 TABLE OF CONTENTS PAGE 1. BRIEF SUMMARY...4 2. METHODS OF ANALYSIS...5 3. ABSORPTION...6 4. DISTRIBUTION...7
More informationPharmacometric Modelling to Support Extrapolation in Regulatory Submissions
Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions Kristin Karlsson, PhD Pharmacometric/Pharmacokinetic assessor Medical Products Agency, Uppsala,Sweden PSI One Day Extrapolation
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationPregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 Women
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2006, p. 2079 2086 Vol. 50, No. 6 0066-4804/06/$08.00 0 doi:10.1128/aac.01596-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Pregnancy-Related
More informationPopulation Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2003, p. 548 553 Vol. 47, No. 2 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.2.548 553.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPaediatric Pharmacology: anaesthetic implications
Paediatric Pharmacology: anaesthetic implications Brian Anderson PhD, FANZCA, FCICM Professor Anaesthesiology University of Auckland New Zealand Duccio di Buoninsegna 1308 A Lack of Knowledge of Pharmacology
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationRP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form
RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form S. LAVANYA* 1, SK. MANSURA BEGUM 1, K. NAGAMALLESWARA RAO 2, K. GAYATHRI DEVI 3 Department of pharmaceutical
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationGlobal Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 350 359 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.350 359.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationPharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives
PCTH 325 Pharmacokinetics Dr. Shabbits jennifer.shabbits@ubc.ca September 12, 2013 Learning Objectives 1. Interpret Concentration vs graphs and use them to calculate half life and predict drug concentration
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationReceived 28 May 2011/Returned for modification 16 July 2011/Accepted 14 September 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5529 5540 Vol. 55, No. 12 0066-4804/11/$12.00 doi:10.1128/aac.00741-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Quantifying
More informationAre Children Small Adults?
Are Children Small Adults? What can modeling offer to (clinical) practice? Catherijne Knibbe, PharmD, PhD Hospital Pharmacist-Clinical Pharmacologist How are children dosed in (clinical) practice? In practice
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationAntiviral Therapy 2016; 21: (doi: /IMP3001)
Antiviral Therapy ; : (doi:.8/imp) Short communication Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir boosted lopinavir on HIV viral load reduction during
More informationTime to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect
Adjustment of k e0 to Reflect True Time Course of Drug Effect by Using Observed Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect Algorithm Reported by Shafer and
More informationPopulation Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester
Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development Leon Aarons Manchester Pharmacy School University of Manchester Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationRaltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110 Clarke DF, Acosta EP, Chain A, Cababasay M, Wang J, Calabrese K, Spector SA, Bryson
More informationPharmacokinetics of Lopinavir in HIV-1 1 infected children
Pharmacokinetics of Lopinavir in HIV-1 1 infected children Hegoburu MS 1 ; Curras V 1 ; Höcht C 1 ; Niselman V 2 ; Mecikovsky D 3 ; Bologna R 3 ; Rubio MC 1 ; Schaiquevich P 4 ; Bramuglia GF 1 1 Cátedra
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationIgnacio Cortínez Anesthesiology Department School of Medicine, Pontificia Universidad Católica de Chile
Recommended doses of Levobupivacaine for TAP Blocks: Development of a pharmacokinetic model and estimation of the risk of symptoms of local anesthetic systemic toxicity Ignacio Cortínez Anesthesiology
More informationClinical pharmacology of propylene glycol in neonates
Clinical pharmacology of propylene glycol in neonates KULO AIDA, DE HOON JAN, RAYYAN MAISSA, VERBESSELT RENE, ALLEGAERT KAREL Center for Clinical Pharmacology and Neonatal Intensive Care Unit University
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHPLC-UV Determination of Abacavir Sulphate in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 19, No. 5 (2007), 3412-3416 HPLC-UV Determination of Abacavir Sulphate in Pharmaceutical Dosage Forms A. SHANTA KUMARI*, K. PRAKASH, K.E.V. NAGOJI and M.E.B. RAO Department
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationPOPULATION PHARMACOKINETICS
POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development 1 Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationThe total global annual burden of P. vivax infections has been
Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy Joel Tarning, a,b Palang Chotsiri, a Vincent
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationA Layperson s Guide to Pediatric Formulation Development
A Layperson s Guide to Pediatric Formulation Development Karen C. Thompson PhD Senior Principal Scientist Preclinical Development Merck Research Laboratory West Point, Pennsylvania Martin J. Gartland PhD
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationPharmacokinetics in pediatric population
Pharmacokinetics in pediatric population Children cannot be considered to be small adults. The physiologic processes that determine drug disposition undergo radical changes during biological maturation.
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More information